China SXT Net Worth
China SXT Net Worth Breakdown | SXTC |
China SXT Net Worth Analysis
China SXT's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including China SXT's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of China SXT's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform China SXT's net worth analysis. One common approach is to calculate China SXT's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares China SXT's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing China SXT's net worth. This approach calculates the present value of China SXT's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of China SXT's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate China SXT's net worth. This involves comparing China SXT's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into China SXT's net worth relative to its peers.
Enterprise Value |
|
To determine if China SXT is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding China SXT's net worth research are outlined below:
| China SXT is way too risky over 90 days horizon | |
| China SXT appears to be risky and price may revert if volatility continues | |
| China SXT has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.93 M. Net Loss for the year was (3.1 M) with profit before overhead, payroll, taxes, and interest of 553.97 K. | |
| China SXT Pharmaceuticals currently holds about 15.52 M in cash with (1.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| China SXT has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange - TipRanks |
China SXT uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in China SXT Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to China SXT's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 30th of October 2023 Upcoming Quarterly Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View |
Know China SXT's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as China SXT is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading China SXT Pharmaceuticals backward and forwards among themselves. China SXT's institutional investor refers to the entity that pools money to purchase China SXT's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of Montreal | 2024-12-31 | 10 K | Bmo Capital Markets Corp. | 2024-12-31 | 10 K | Ubs Group Ag | 2024-12-31 | 8.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Gsa Capital Partners Llp | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Baader Bank Inc | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
Follow China SXT's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.34 M.Market Cap |
|
Project China SXT's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.15) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.13) | (0.15) | |
| Return On Equity | (0.26) | (0.24) |
When accessing China SXT's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures China SXT's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of China SXT's profitability and make more informed investment decisions.
Please note, the presentation of China SXT's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, China SXT's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of China SXT's management manipulating its earnings.
Evaluate China SXT's management efficiency
China SXT Pharmaceuticals has return on total asset (ROA) of (0.0497) % which means that it has lost $0.0497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2165) %, meaning that it created substantial loss on money invested by shareholders. China SXT's management efficiency ratios could be used to measure how well China SXT manages its routine affairs as well as how well it operates its assets and liabilities. As of March 24, 2025, Return On Tangible Assets is expected to decline to -0.15. The current year's Return On Capital Employed is expected to grow to -0.19. At present, China SXT's Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 11.4 M, whereas Total Assets are forecasted to decline to about 21.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 18.47 | 17.55 | |
| Tangible Book Value Per Share | 18.44 | 17.52 | |
| Enterprise Value Over EBITDA | (1.03) | (0.97) | |
| Price Book Value Ratio | 0.95 | 0.90 | |
| Enterprise Value Multiple | (1.03) | (0.97) | |
| Price Fair Value | 0.95 | 0.90 | |
| Enterprise Value | 2.4 M | 2.3 M |
Understanding the operational decisions made by China SXT management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 0.4132 | Revenue | Quarterly Revenue Growth 0.295 | Revenue Per Share | Return On Equity |
China SXT Corporate Filings
6K | 19th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 21st of January 2025 Other Reports | ViewVerify | |
13A | 25th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify |
China SXT Earnings per Share Projection vs Actual
When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (28.58) | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.